Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Cite this paper

@article{Ichihara2015PhaseIT, title={Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.}, author={Eiki Ichihara and Katsuyuki Hotta and Naoyuki Nogami and Shoichi Kuyama and Daizo Kishino and Masanori Fujii and Toshiyuki Kozuki and Masahiro Tabata and Daijiro Harada and Kenichi Chikamori and Keisuke Aoe and Hiroshi Ueoka and Shinobu Hosokawa and Akihiro Bessho and Akiko Hisamoto-Sato and Toshio Kubo and Isao Oze and Nagio Takigawa and Mitsune Tanimoto and Katsuyuki Kiura}, journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer}, year={2015}, volume={10 3}, pages={486-91} }